Increasing pressure on health systems to reduce overall spending has made commercialization in public markets challenging. However, the growing middle class in many global markets, coupled with rising demand for better healthcare, provides an opportunity for companies to turn to the private market for higher value growth. The private market also presents opportunities for vaccines’ first entry into some countries—especially when getting inclusion into national immunization programs (NIP) may take longer. Additionally, by entering into countries through the private market, pharma companies can drive early adoption, build opinion leaders and generate early evidence, which can facilitate future NIP inclusion.
In this webinar, ZS vaccines leaders Emmanuel Colliot and Adi Natu talk with GSK’s Durga Bobba and HHI’s Yves Vanthillo about opportunities in the private market for vaccines. Attendees will learn:
- The barriers facing manufacturers in the private market globally
- About the trends driving the private market’s future and the roles various stakeholders (consumers, vaccinators, policymakers, funders) play in shaping its evolution
- The innovations B2C markets outside of vaccines can offer and strategies to optimize access
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
